ArticleCancer cytopathology2016
Analytical validity of a microRNA-based assay for diagnosing indeterminate thyroid FNA smears from routinely prepared cytology slides.
Article in Cancer cytopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Thyroseq v3, Afirma GSC, and microRNA Panels Versus Previous Molecular Tests in the Preoperative Diagnosis of Indeterminate Thyroid Nodules: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- The value of preoperative molecular testing in the management of Bethesda V and Bethesda VI thyroid tumors.Hormones (Athens, Greece) · 2025Review
- miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology?Future cardiology · 2024Review
- Molecular testing in indeterminate thyroid nodules: an additional tool for clinical decision-making.Pathologica · 2023Review
- Review
- Article
- Molecular diagnostics in the evaluation of thyroid nodules: Current use and prospective opportunities.Frontiers in endocrinology · 2023Review
- Molecular Characterization of Thyroid Follicular Lesions in the Era of "Next-Generation" Techniques.Frontiers in endocrinology · 2022Review
- Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.Cancer cytopathology · 2021Article
- Translational Potential of Epigenetic-Based Markers on Fine-Needle Aspiration Thyroid Specimens.Frontiers in medicine · 2021Review
- Article
- Indeterminate thyroid nodules in the era of molecular genomics.Molecular genetics & genomic medicine · 2020Review
- Molecular markers for the classification of cytologically indeterminate thyroid nodules.Journal of endocrinological investigation · 2020Review
- Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives.Frontiers in oncology · 2020Review
- Article
- Review
- Utility of microdissected cytology smears for molecular analysis of thyroid malignancy.Diagnostic cytopathology · 2019Article
- Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy.International journal of molecular sciences · 2019Review
- Serum miR-22 may be a biomarker for papillary thyroid cancer.Oncology letters · 2019Article
- Loss of DNA methylation is related to increased expression of miR-21 and miR-146b in papillary thyroid carcinoma.Clinical epigenetics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe majority of thyroid nodules are diagnosed using fine-needle aspiration (FNA) biopsies. The authors recently described the clinical validation of a molecular microRNA-based assay, RosettaGX Reveal, which can diagnose thyroid nodules as benign or suspicious using a single stained FNA smear. This paper describes the analytical validation of the assay.
methodsMore than 800 FNA slides were tested, including slides stained with Romanowsky-type and Papanicolaou stains. The assay was examined for the following features: intranodule concordance, effect of stain type, minimal acceptable RNA amounts, performance on low numbers of thyroid cells, effect of time since sampling, and analytical sensitivity, specificity, and reproducibility.
resultsThe assay can be run on FNA slides for which as little as 1% of the cells are thyroid epithelial cells or from which only 5 ng of RNA have been extracted. Samples composed entirely of blood failed quality control and were not classified. Stain type did not affect performance. All slides were stored at room temperature. However, the length of time between FNA sampling and processing did not affect assay performance. There was a high level of concordance between laboratories (96%), and the concordance for slides created from the same FNA pass was 93%.
conclusionsThe microRNA-based assay was robust to various physical processing conditions and to differing sample characteristics. Given the assay's performance, robustness, and use of routinely prepared FNA slides, it has the potential to provide valuable aid for physicians in the diagnosis of thyroid nodules. Cancer Cytopathol 2016;124:711-21. © 2016 Rosetta Genomics. Cancer Cytopathology published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.